A Phase I Study to Investigate the Safety, Pharmacokinetic Profile and the Efficacy of EDO-S101, a First-in-Class Alkylating HDACi Fusion Molecule in Patients With Newly Di-Agnosed MGMT-Promoter Unmethylated Glioblastoma
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Tinostamustine (Primary)
- Indications Glioblastoma; Glioma; Gliosarcoma
- Focus Adverse reactions
Most Recent Events
- 28 Jun 2024 Status changed from active, no longer recruiting to completed.
- 04 Apr 2023 Planned End Date changed from 31 Oct 2022 to 30 Dec 2024.
- 04 Apr 2023 Planned primary completion date changed from 31 Oct 2022 to 30 Dec 2024.